# GeDiPNet Cluster 21 -- Enriched Pathways -- generated 2026-10-09 03:36:26
# Pathway enrichment: KEGG + Reactome, upper-tail hypergeometric test, Benjamini-Hochberg FDR-corrected. Fold enrichment = (overlap / cluster gene count) / (pathway gene count / universe size). Top 15 pathways per cluster by q-value. See scripts/build_cluster_enrichment.php on gedipnet.bicnirrh.res.in. Data as of: 2026-10-09 03:30:08.
Pathway	Source	Overlap Genes	Overlap Gene Names	Pathway Gene Count	Cluster Gene Count	Fold Enrichment	P-value	FDR Q-value
Pathways in cancer	KEGG	224	ESR1, FGFR2, ABL1, AKT1, AKT2, ALK, APC2, AR, ARAF, BAX, BCL2, BIRC2	533	1863	2.71	2.067e-51	3.628e-47
Prostate cancer	KEGG	71	FGFR2, AKT1, AKT2, AR, ARAF, BCL2, CCND1, CCNE1, CDKN1B, CTNNB1, E2F1, EGF	98	1863	4.67	1.476e-36	6.299e-33
Endocrine resistance	KEGG	63	ESR1, AKT1, AKT2, ARAF, BAX, BCL2, CCND1, CDKN1B, CDKN2A, CYP2D6, DLL1, DLL4	99	1863	4.10	1.633e-27	3.554e-24
Breast cancer	KEGG	79	ESR1, AKT1, AKT2, APC2, ARAF, BAX, BRCA1, BRCA2, CCND1, CTNNB1, DLL1, DLL4	148	1863	3.44	7.444e-27	1.449e-23
PI3K-Akt signaling pathway	KEGG	138	FGFR2, AKT1, AKT2, AREG, ARTN, BCL2, BRCA1, CCND1, CCNE1, CDKN1B, CSF1, CSF1R	361	1863	2.46	1.245e-26	2.383e-23
Non-small cell lung cancer	KEGG	52	AKT1, AKT2, ALK, ARAF, BAX, CCND1, CDKN2A, E2F1, EGF, EGFR, ERBB2, HRAS	73	1863	4.59	1.655e-26	3.061e-23
Proteoglycans in cancer	KEGG	95	ESR1, AKT1, AKT2, ARAF, CAV1, CCND1, CTNNB1, EGFR, ERBB2, ERBB3, FGFR1, FLNA	204	1863	3.00	4.177e-26	7.357e-23
Bladder cancer	KEGG	37	ARAF, CCND1, CDH1, CDKN2A, CXCL8, E2F1, EGF, EGFR, ERBB2, HRAS, KRAS, MDM2	41	1863	5.82	4.455e-26	7.725e-23
Pancreatic cancer	KEGG	52	AKT1, AKT2, ARAF, BAX, BRCA2, CCND1, CDKN2A, E2F1, EGF, EGFR, ERBB2, KRAS	77	1863	4.35	9.302e-25	1.395e-21
Melanoma	KEGG	50	AKT1, AKT2, ARAF, BAX, CCND1, CDH1, CDKN2A, E2F1, EGF, EGFR, FGF10, FGF3	73	1863	4.42	2.736e-24	3.995e-21
EGFR tyrosine kinase inhibitor resistance	KEGG	52	FGFR2, AKT1, AKT2, ARAF, BAX, BCL2, EGF, EGFR, ERBB2, ERBB3, GSK3B, HRAS	80	1863	4.19	1.440e-23	1.795e-20
Hepatocellular carcinoma	KEGG	81	AKT1, AKT2, APC2, ARAF, ARID1A, BAX, CCND1, CDKN2A, CTNNB1, E2F1, EGFR, GSK3B	170	1863	3.07	3.079e-23	3.662e-20
Gastric cancer	KEGG	75	FGFR2, ABCB1, AKT1, AKT2, APC2, ARAF, BAX, BCL2, CCND1, CCNE1, CDH1, CDKN1B	150	1863	3.22	3.102e-23	3.662e-20
Interleukin-4 and Interleukin-13 signaling	Reactome	61	AKT1, BCL2, BIRC5, CCND1, CXCL8, FN1, FOS, HIF1A, HMOX1, HSP90AA1, IL10, IL1B	108	1863	3.64	9.745e-23	1.103e-19
Lipid and atherosclerosis	KEGG	93	AKT1, AKT2, BAX, BCL2, CASP7, CASP8, CD40, CXCL2, CXCL3, CXCL8, CYP1A1, DDIT3	216	1863	2.78	1.595e-22	1.766e-19